{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:31:49Z","timestamp":1791498709438,"version":"4.3.4"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AstraZeneca providing funding to support experiments"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The therapeutic potential of targeting PI3K\/AKT\/PTEN signalling in B-cell malignancies remains attractive. Whilst PI3K-\u03b1\/\u03b4 inhibitors demonstrate clinical benefit in certain B-cell lymphomas, PI3K signalling inhibitors have been inadequate in relapsed\/refractory diffuse large B-cell lymphoma (DLBCL) in part, due to treatment related toxicities. Clinically, AKT inhibitors exhibit a differentiated tolerability profile offering an alternative approach for treating patients with B-cell malignancies. To explore how AKT inhibition complements other potential therapeutics in the treatment of DLBCL patients, an in vitro combination screen was conducted across a panel of DLCBL cell lines. The AKT inhibitor, capivasertib, in combination with the BCL-2 inhibitor, venetoclax, produced notable therapeutic benefit in preclinical models of DLBCL. Capivasertib and venetoclax rapidly induced caspase and PARP cleavage in GCB-DLBCL\n                    <jats:italic>PTEN<\/jats:italic>\n                    wildtype cell lines and those harbouring\n                    <jats:italic>PTEN<\/jats:italic>\n                    mutations or reduced PTEN protein, driving prolonged tumour growth inhibition in DLBCL cell line and patient derived xenograft lymphoma models. The addition of the rituximab further deepened the durability of capivasertib and venetoclax responses in a RCHOP refractory DLBCL in vivo models. These findings provide preclinical evidence for the rational treatment combination of AKT and BCL-2 inhibitors using capivasertib and venetoclax respectively alongside anti-CD20 antibody supplementation for treatment of patients with DLBCL.\n                  <\/jats:p>","DOI":"10.1038\/s41375-024-02401-9","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T03:02:33Z","timestamp":1726455753000},"page":"2663-2674","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma"],"prefix":"10.1038","volume":"38","author":[{"given":"Brandon S.","family":"Willis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Mongeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Dry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"India L.","family":"Neveras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadezda","family":"Bryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghana","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Roderick-Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Reimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Tuskova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Klener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome T.","family":"Mettetal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4728-1693","authenticated-orcid":false,"given":"Georg","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8511-0588","authenticated-orcid":false,"given":"Simon T.","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,16]]},"reference":[{"key":"2401_CR1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390.","journal-title":"Blood"},{"key":"2401_CR2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","volume":"37","author":"GW Wright","year":"2020","unstructured":"Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell. 2020;37:551\u201368.e14.","journal-title":"Cancer Cell"},{"key":"2401_CR3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/PPO.0000000000000450","volume":"26","author":"M Roschewski","year":"2020","unstructured":"Roschewski M, Phelan JD, Wilson WH. Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma. Cancer J. 2020;26:195\u2013205.","journal-title":"Cancer J"},{"key":"2401_CR4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trneny M, Sharman JP, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N. Engl J Med. 2022;386:351\u201363.","journal-title":"N. Engl J Med"},{"key":"2401_CR5","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.ajpath.2017.04.009","volume":"187","author":"J Wang","year":"2017","unstructured":"Wang J, Xu-Monette ZY, Jabbar KJ, Shen Q, Manyam GC, Tzankov A, et al. AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. Am J Pathol. 2017;187:1700\u201316.","journal-title":"Am J Pathol"},{"key":"2401_CR6","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.4161\/cc.26575","volume":"12","author":"M Pfeifer","year":"2013","unstructured":"Pfeifer M, Lenz G. PI3K\/AKT addiction in subsets of diffuse large B-cell lymphoma. Cell Cycle. 2013;12:3347\u20138.","journal-title":"Cell Cycle"},{"key":"2401_CR7","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/blood-2016-12-758599","volume":"130","author":"T Erdmann","year":"2017","unstructured":"Erdmann T, Klener P, Lynch JT, Grau M, Vo\u010dkov\u00e1 P, Molinsky J, et al. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. Blood. 2017;130:310\u201322.","journal-title":"Blood"},{"key":"2401_CR8","doi-asserted-by":"crossref","first-page":"81794","DOI":"10.18632\/oncotarget.20864","volume":"8","author":"GN Pongas","year":"2017","unstructured":"Pongas GN, Annunziata CM, Staudt LM. PI3K\u03b4 inhibition causes feedback activation of PI3K\u03b1 in the ABC subtype of diffuse large B-cell lymphoma. Oncotarget. 2017;8:81794\u2013802.","journal-title":"Oncotarget"},{"key":"2401_CR9","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ccr.2013.05.002","volume":"23","author":"L Chen","year":"2013","unstructured":"Chen L, Monti S, Juszczynski P, Ouyang J, Chapuy B, Neuberg D, et al. SYK inhibition modulates distinct PI3K\/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell. 2013;23:826\u201338.","journal-title":"Cancer Cell"},{"key":"2401_CR10","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","volume":"28","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Morschhauser F, Bouabdallah K, Bron D, Cunningham D, Assouline SE, et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol. 2017;28:2169\u201378.","journal-title":"Ann Oncol"},{"key":"2401_CR11","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1038\/s41375-020-0743-y","volume":"34","author":"G Lenz","year":"2020","unstructured":"Lenz G, Hawkes E, Verhoef G, Haioun C, Thye Lim S, Seog Heo D, et al. Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma. Leukemia. 2020;34:2184\u201397.","journal-title":"Leukemia"},{"key":"2401_CR12","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N. Engl J Med. 2023;388:2058\u201370.","journal-title":"N. Engl J Med"},{"key":"2401_CR13","doi-asserted-by":"crossref","first-page":"9163","DOI":"10.18632\/oncotarget.7036","volume":"7","author":"SA Ezell","year":"2016","unstructured":"Ezell SA, Wang S, Bihani T, Lai Z, Grosskurth SE, Tepsuporn S, et al. Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma. Oncotarget. 2016;7:9163\u201374.","journal-title":"Oncotarget"},{"key":"2401_CR14","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1182\/blood.2020006784","volume":"138","author":"W Xu","year":"2021","unstructured":"Xu W, Berning P, Lenz G. Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma. Blood. 2021;138:1110\u20139.","journal-title":"Blood"},{"key":"2401_CR15","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.trecan.2016.07.001","volume":"2","author":"S Cory","year":"2016","unstructured":"Cory S, Roberts AW, Colman PM, Adams JM. Targeting BCL-2-like Proteins to Kill Cancer Cells. Trends Cancer. 2016;2:443\u201360.","journal-title":"Trends Cancer"},{"key":"2401_CR16","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N. Engl J Med. 2020;383:617\u201329.","journal-title":"N. Engl J Med"},{"key":"2401_CR17","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","volume":"17","author":"S Stilgenbauer","year":"2016","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17:768\u201378.","journal-title":"Lancet Oncol"},{"key":"2401_CR18","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1182\/bloodadvances.2020002580","volume":"4","author":"H Scholze","year":"2020","unstructured":"Scholze H, Stephenson RE, Reynolds R, Shah S, Puri R, Butler SD, et al. Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes. Blood Adv. 2020;4:5226\u201331.","journal-title":"Blood Adv"},{"key":"2401_CR19","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1182\/blood.2020006578","volume":"137","author":"F Morschhauser","year":"2021","unstructured":"Morschhauser F, Feugier P, Flinn IW, Gasiorowski R, Greil R, Illes A, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood. 2021;137:600\u20139.","journal-title":"Blood"},{"key":"2401_CR20","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.525","volume":"6","author":"GS Choudhary","year":"2015","unstructured":"Choudhary GS, Al-Harbi S, Mazumder S, Hill BT, Smith MR, Bodo J, et al. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies. Cell Death Dis. 2015;6:e1593.","journal-title":"Cell Death Dis"},{"key":"2401_CR21","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1158\/1535-7163.MCT-08-0268","volume":"7","author":"S Ackler","year":"2008","unstructured":"Ackler S, Xiao Y, Mitten MJ, Foster K, Oleksijew A, Refici M, et al. ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Mol Cancer Ther. 2008;7:3265\u201374.","journal-title":"Mol Cancer Ther"},{"key":"2401_CR22","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1158\/0008-5472.CAN-10-4531","volume":"71","author":"JL Coloff","year":"2011","unstructured":"Coloff JL, Macintyre AN, Nichols AG, Liu T, Gallo CA, Plas DR, et al. Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition. Cancer Res. 2011;71:5204\u201313.","journal-title":"Cancer Res"},{"key":"2401_CR23","doi-asserted-by":"crossref","first-page":"35202","DOI":"10.18632\/oncotarget.6051","volume":"6","author":"JS Lee","year":"2015","unstructured":"Lee JS, Tang SS, Ortiz V, Vo TT, Fruman DA. MCL-1-independent mechanisms of synergy between dual PI3K\/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma. Oncotarget. 2015;6:35202\u201317.","journal-title":"Oncotarget"},{"key":"2401_CR24","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1200\/JCO.20.03531","volume":"39","author":"AJ Davies","year":"2021","unstructured":"Davies AJ. Precision Medicine in DLBCL: Are We There Yet? J Clin Oncol. 2021;39:1314\u20136.","journal-title":"J Clin Oncol"},{"key":"2401_CR25","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1158\/1535-7163.MCT-11-0824-T","volume":"11","author":"BR Davies","year":"2012","unstructured":"Davies BR, Greenwood H, Dudley P, Crafter C, Yu DH, Zhang J, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012;11:873\u201387.","journal-title":"Mol Cancer Ther"},{"key":"2401_CR26","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202\u20138.","journal-title":"Nat Med"},{"key":"2401_CR27","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma. Blood. 1997;90:2188\u201395.","journal-title":"Blood"},{"key":"2401_CR28","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3892\/ijo.2015.3062","volume":"47","author":"C Crafter","year":"2015","unstructured":"Crafter C, Vincent JP, Tang E, Dudley P, James NH, Klinowska T, et al. Combining AZD8931, a novel EGFR\/HER2\/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models. Int J Oncol. 2015;47:446\u201354.","journal-title":"Int J Oncol"},{"key":"2401_CR29","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41375-022-01749-0","volume":"37","author":"W Xu","year":"2023","unstructured":"Xu W, Berning P, Erdmann T, Grau M, Bettazova N, Zapukhlyak M, et al. mTOR inhibition amplifies the anti-lymphoma effect of PI3Kbeta\/delta blockage in diffuse large B-cell lymphoma. Leukemia. 2023;37:178\u201389.","journal-title":"Leukemia"},{"key":"2401_CR30","doi-asserted-by":"crossref","first-page":"94","DOI":"10.4103\/0976-500X.72351","volume":"1","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. J Pharm Pharmacother. 2010;1:94\u201399.","journal-title":"J Pharm Pharmacother"},{"key":"2401_CR31","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0092-8674(00)80595-4","volume":"96","author":"A Brunet","year":"1999","unstructured":"Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell. 1999;96:857\u201368.","journal-title":"Cell"},{"key":"2401_CR32","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/378785a0","volume":"378","author":"DAE Cross","year":"1995","unstructured":"Cross DAE, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378:785\u20139.","journal-title":"Nature"},{"key":"2401_CR33","doi-asserted-by":"crossref","first-page":"10189","DOI":"10.1074\/jbc.M210837200","volume":"278","author":"KS Kovacina","year":"2003","unstructured":"Kovacina KS, Park GY, Bae SS, Guzzetta AW, Schaefer E, Birnbaum MJ, et al. Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. J Biol Chem. 2003;278:10189\u201394.","journal-title":"J Biol Chem"},{"key":"2401_CR34","doi-asserted-by":"crossref","first-page":"17179","DOI":"10.1074\/jbc.274.24.17179","volume":"274","author":"G Rena","year":"1999","unstructured":"Rena G, Guo S, Cichy SC, Unterman TG, Cohen P. Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. J Biol Chem. 1999;274:17179\u201383.","journal-title":"J Biol Chem"},{"key":"2401_CR35","doi-asserted-by":"crossref","first-page":"6541","DOI":"10.1002\/j.1460-2075.1996.tb01045.x","volume":"15","author":"DR Alessi","year":"1996","unstructured":"Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996;15:6541\u201351.","journal-title":"EMBO J"},{"key":"2401_CR36","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0960-9822(06)00122-9","volume":"7","author":"DR Alessi","year":"1997","unstructured":"Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PRJ, Reese CB, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B\u03b1. Curr Biol. 1997;7:261\u20139.","journal-title":"Curr Biol"},{"key":"2401_CR37","doi-asserted-by":"crossref","first-page":"40406","DOI":"10.1074\/jbc.M508361200","volume":"280","author":"RC Hresko","year":"2005","unstructured":"Hresko RC, Mueckler M. mTOR.RICTOR is the Ser473 kinase for Akt\/protein kinase B in 3T3-L1 adipocytes. J Biol Chem. 2005;280:40406\u201316.","journal-title":"J Biol Chem"},{"key":"2401_CR38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cell.2006.08.033","volume":"127","author":"E Jacinto","year":"2006","unstructured":"Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, et al. SIN1\/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell. 2006;127:125\u201337.","journal-title":"Cell"},{"key":"2401_CR39","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","volume":"307","author":"DD Sarbassov","year":"2005","unstructured":"Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex. Science. 2005;307:1098\u2013101.","journal-title":"Science"},{"key":"2401_CR40","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1128\/MCB.22.17.6247-6260.2002","volume":"22","author":"MP Scheid","year":"2002","unstructured":"Scheid MP, Marignani PA, Woodgett JR. Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B. Mol Cell Biol. 2002;22:6247\u201360.","journal-title":"Mol Cell Biol"},{"key":"2401_CR41","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1126\/science.279.5351.710","volume":"279","author":"L Stephens","year":"1998","unstructured":"Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, Holmes AB, et al. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5- trisphosphate-dependent activation of protein kinase B. Science. 1998;279:710\u20134.","journal-title":"Science"},{"key":"2401_CR42","doi-asserted-by":"crossref","first-page":"7863","DOI":"10.1038\/sj.onc.1208069","volume":"23","author":"M Herrant","year":"2004","unstructured":"Herrant M, Jacquel A, Marchetti S, Belhacene N, Colosetti P, Luciano F, et al. Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. Oncogene. 2004;23:7863\u201373.","journal-title":"Oncogene"},{"key":"2401_CR43","doi-asserted-by":"crossref","first-page":"10491","DOI":"10.1074\/jbc.M412819200","volume":"280","author":"C Weng","year":"2005","unstructured":"Weng C, Li Y, Xu D, Shi Y, Tang H. Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells. J Biol Chem. 2005;280:10491\u201310500.","journal-title":"J Biol Chem"},{"key":"2401_CR44","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1038\/sj.cdd.4401963","volume":"13","author":"JE Chipuk","year":"2006","unstructured":"Chipuk JE, Bouchier-Hayes L, Green DR. Mitochondrial outer membrane permeabilization during apoptosis: the innocent bystander scenario. Cell Death Differ. 2006;13:1396\u2013402.","journal-title":"Cell Death Differ"},{"key":"2401_CR45","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.tcb.2008.01.007","volume":"18","author":"JE Chipuk","year":"2008","unstructured":"Chipuk JE, Green DR. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol. 2008;18:157\u201364.","journal-title":"Trends Cell Biol"},{"key":"2401_CR46","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/cdd.2017.186","volume":"25","author":"J Kale","year":"2018","unstructured":"Kale J, Osterlund EJ, Andrews DW. BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ. 2018;25:65\u201380.","journal-title":"Cell Death Differ"},{"key":"2401_CR47","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nrm2952","volume":"11","author":"SW Tait","year":"2010","unstructured":"Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 2010;11:621\u201332.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2401_CR48","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/bit.22541","volume":"105","author":"GJ Cost","year":"2010","unstructured":"Cost GJ, Freyvert Y, Vafiadis A, Santiago Y, Miller JC, Rebar E, et al. BAK and BAX deletion using zinc-finger nucleases yields apoptosis-resistant CHO cells. Biotechnol Bioeng. 2010;105:330\u201340.","journal-title":"Biotechnol Bioeng"},{"key":"2401_CR49","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1097-2765(00)00136-2","volume":"6","author":"T Lindsten","year":"2000","unstructured":"Lindsten T, Ross AJ, King A, Zong W-X, Rathmell JC, Shiels HA, et al. The Combined Functions of Proapoptotic Bcl-2 Family Members Bak and Bax Are Essential for Normal Development of Multiple Tissues. Mol Cell. 2000;6:1389\u201399.","journal-title":"Mol Cell"},{"key":"2401_CR50","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1126\/science.1059108","volume":"292","author":"MC Wei","year":"2001","unstructured":"Wei MC, Zong WX, Cheng EHY, Lindsten T, Panoutsakopoulou V, Ross AJ, et al. Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science. 2001;292:727\u201330.","journal-title":"Science"},{"key":"2401_CR51","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/s41374-022-00784-w","volume":"102","author":"R Jaksa","year":"2022","unstructured":"Jaksa R, Karolova J, Svaton M, Kazantsev D, Grajciarova M, Pokorna E, et al. Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas. Lab Invest. 2022;102:957\u201365.","journal-title":"Lab Invest"},{"key":"2401_CR52","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1158\/1078-0432.CCR-15-1191","volume":"22","author":"M Klanova","year":"2016","unstructured":"Klanova M, Andera L, Brazina J, Svadlenka J, Benesova S, Soukup J, et al. Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma. Clin Cancer Res. 2016;22:1138\u201349.","journal-title":"Clin Cancer Res"},{"key":"2401_CR53","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-023-00581-8","volume":"9","author":"L Hopcroft","year":"2023","unstructured":"Hopcroft L, Wigmore EM, Williamson SC, Ros S, Eberlein C, Moss JI, et al. Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models. NPJ Breast Cancer. 2023;9:64.","journal-title":"NPJ Breast Cancer"},{"key":"2401_CR54","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/s41416-024-02614-w","volume":"130","author":"C Eberlein","year":"2024","unstructured":"Eberlein C, Williamson SC, Hopcroft L, Ros S, Moss JI, Kerr J, et al. Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. Br J Cancer. 2024;130:1377\u201387.","journal-title":"Br J Cancer"},{"key":"2401_CR55","doi-asserted-by":"crossref","first-page":"22128","DOI":"10.18632\/oncotarget.8031","volume":"7","author":"JT Lynch","year":"2016","unstructured":"Lynch JT, McEwen R, Crafter C, McDermott U, Garnett MJ, Barry ST, et al. Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen. Oncotarget. 2016;7:22128\u201339.","journal-title":"Oncotarget"},{"key":"2401_CR56","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/blood-2018-08-872465","volume":"133","author":"K Bojarczuk","year":"2019","unstructured":"Bojarczuk K, Wienand K, Ryan JA, Chen L, Villalobos-Ortiz M, Mandato E, et al. Targeted inhibition of PI3Kalpha\/delta is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL. Blood. 2019;133:70\u201380.","journal-title":"Blood"},{"key":"2401_CR57","doi-asserted-by":"crossref","first-page":"7584","DOI":"10.1158\/1078-0432.CCR-17-0676","volume":"23","author":"JT Lynch","year":"2017","unstructured":"Lynch JT, Polanska UM, Delpuech O, Hancox U, Trinidad AG, Michopoulos F, et al. Inhibiting PI3Kbeta with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors. Clin Cancer Res. 2017;23:7584\u201395.","journal-title":"Clin Cancer Res"},{"key":"2401_CR58","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1158\/1535-7163.MCT-18-0183","volume":"17","author":"JT Lynch","year":"2018","unstructured":"Lynch JT, Polanska UM, Hancox U, Delpuech O, Maynard J, Trigwell C, et al. Combined Inhibition of PI3Kbeta and mTOR Inhibits Growth of PTEN-null Tumors. Mol Cancer Ther. 2018;17:2309\u201319.","journal-title":"Mol Cancer Ther"},{"key":"2401_CR59","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.7150\/ijbs.89942","volume":"20","author":"F Fontana","year":"2024","unstructured":"Fontana F, Giannitti G, Marchesi S, Limonta P. The PI3K\/Akt Pathway and Glucose Metabolism: A Dangerous Liaison in Cancer. Int J Biol Sci. 2024;20:3113\u201325.","journal-title":"Int J Biol Sci"},{"key":"2401_CR60","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1038\/s41388-022-02482-9","volume":"41","author":"S Dunn","year":"2022","unstructured":"Dunn S, Eberlein C, Yu J, Gris-Oliver A, Ong SH, Yelland U, et al. AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kbeta\/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors. Oncogene. 2022;41:5046\u201360.","journal-title":"Oncogene"},{"key":"2401_CR61","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.40","volume":"7","author":"A Paulus","year":"2017","unstructured":"Paulus A, Akhtar S, Yousaf H, Manna A, Paulus SM, Bashir Y, et al. Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. Blood Cancer J. 2017;7:e565.","journal-title":"Blood Cancer J"},{"key":"2401_CR62","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1158\/1078-0432.CCR-17-3004","volume":"24","author":"LV Pham","year":"2018","unstructured":"Pham LV, Huang S, Zhang H, Zhang J, Bell T, Zhou S, et al. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas. Clin Cancer Res. 2018;24:3967\u201380.","journal-title":"Clin Cancer Res"},{"key":"2401_CR63","doi-asserted-by":"crossref","first-page":"35202","DOI":"10.18632\/oncotarget.6051","volume":"6","author":"J Scott Lee","year":"2015","unstructured":"Scott Lee J, Tang SS, Ortiz V, Vo TT, Fruman DA. MCL-1-independent mechanisms of synergy between dual PI3K\/ mTOR and BCL-2 inhibition in diffuse large B cell lymphoma. Oncotarget. 2015;6:35202\u201317.","journal-title":"Oncotarget"},{"key":"2401_CR64","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1158\/1541-7786.MCR-11-0394","volume":"10","author":"LC Spender","year":"2012","unstructured":"Spender LC, Inman GJ. Phosphoinositide 3-kinase\/AKT\/mTORC1\/2 signaling determines sensitivity of Burkitt\u2019s lymphoma cells to BH3 mimetics. Mol Cancer Res. 2012;10:347\u201359.","journal-title":"Mol Cancer Res"},{"key":"2401_CR65","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.88","volume":"5","author":"DC Phillips","year":"2015","unstructured":"Phillips DC, Xiao Y, Lam LT, Litvinovich E, Roberts-Rapp L, Souers AJ, et al. Loss in MCL-1 function sensitizes non-Hodgkin\u2019s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). Blood Cancer J. 2015;5:e368.","journal-title":"Blood Cancer J"},{"key":"2401_CR66","volume":"9","author":"AE Tron","year":"2018","unstructured":"Tron AE, Belmonte MA, Adam A, Aquila BM, Boise LH, Chiarparin E, et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat Commun. 2018;9:5341.","journal-title":"Nat Commun"},{"key":"2401_CR67","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1158\/0008-5472.CAN-17-3024","volume":"78","author":"M Rahmani","year":"2018","unstructured":"Rahmani M, Nkwocha J, Hawkins E, Pei X, Parker RE, Kmieciak M, et al. Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells. Cancer Res. 2018;78:3075\u201386.","journal-title":"Cancer Res"},{"key":"2401_CR68","doi-asserted-by":"crossref","first-page":"e45235","DOI":"10.15252\/embr.201745235","volume":"19","author":"J Kale","year":"2018","unstructured":"Kale J, Kutuk O, Brito GC, Andrews TS, Leber B, Letai A, et al. Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance. EMBO Rep. 2018;19:e45235.","journal-title":"EMBO Rep"},{"key":"2401_CR69","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s41419-018-0943-9","volume":"9","author":"L Sun","year":"2018","unstructured":"Sun L, Huang Y, Liu Y, Zhao Y, He X, Zhang L, et al. Ipatasertib, a novel Akt inhibitor, induces transcription factor FoxO3a and NF-\u03baB directly regulates PUMA-dependent apoptosis. Cell death Dis. 2018;9:911.","journal-title":"Cell death Dis"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02401-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02401-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02401-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T06:02:38Z","timestamp":1732514558000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02401-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,16]]},"references-count":69,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2401"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02401-9","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,16]]},"assertion":[{"value":"15 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.W., K.M., H.D., I.N., A.R., M.P., N.B., J.R.R., C.R., J.M., and S.B. are current or former AstraZeneca employees and shareholders.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}